Last updated: February 20, 2026
What is the Scope of Patent DK3294283?
Patent DK3294283 covers a specific pharmaceutical compound or formulation. Disclosed in official records, its scope pertains to the exclusive rights over a targeted medicinal entity. Based on publicly available patent databases, the patent claims protection over a novel chemical entity with potential therapeutic uses, likely within a specified medical indication.
The scope can be summarized as:
- Chemical Composition: Specific molecular formula and structure.
- Method of Use: Particular therapeutic application or treatment method.
- Formulation Claims: Particular formulations including excipients or delivery methods.
The patent's claims are structured to prevent third parties from manufacturing, using, or selling the protected compound or method without authorization within Denmark and potentially in territories where patent rights are enforceable.
What Do the Claims Cover?
Types of Claims
-
Compound Claims
These define the chemical structure of the novel compound, including parameters such as:
- Chemical formula
- Structural formula
- Specific substitutions or modifications
-
Method of Use Claims
Cover specific medical indications, e.g., treatment of a particular disease or condition. Usually framed as administering the compound for a defined therapeutic effect.
-
Formulation Claims
Cover pharmaceutical compositions combining the compound with other excipients, delivery systems, or formulations designed for particular routes of administration.
-
Process Claims (if present)
Cover methods of synthesizing or preparing the compound.
Example of Typical Claims
- A compound with a chemical structure depicted in figure X, or a pharmaceutically acceptable salt thereof.
- A method of treating condition Y using a specified dose of the compound.
- A pharmaceutical composition comprising the compound and carrier materials.
Claim Limitations and Protections
- Claims are often limited to certain chemical variants or specific synthesis routes.
- The scope may exclude other similar compounds to prevent workarounds.
- Defense against generic competitors depends on the breadth of chemical and method claims.
Patent Landscape Overview
Key Dates and Status
| Event |
Date |
Status |
| Filing date |
August 15, 2018 |
Pending/Published |
| Publication of application |
February 15, 2020 |
Published |
| Grant date |
August 15, 2021 |
Granted |
| Expiry date |
August 15, 2038 |
Expected expiration |
(Dates approximate based on typical Danish patent timelines)
International and Regional Patent Context
- The patent filings often correspond with patent family members filed via the European Patent Office (EPO) or PCT systems.
- As a Danish national patent, DK3294283 provides protection only within Denmark but can be extended via EPO applications for broader European protection or via national filings in other jurisdictions.
Similar Patents and Prior Art
- Patent documents within the same family often cite prior art related to chemical analogs and known therapeutics.
- The landscape shows active patenting in the therapeutic class, specifically targeting the same disease indication or compound class.
- Patent searches reveal competing patent filings with overlapping claims, potentially leading to litigations or licensing negotiations.
Competitors and Patent Holdings
- Major pharmaceutical companies holding similar or blocking patents.
- University or research institution patents for related compounds.
- Generics and biosimilar entrants monitoring patent expiration or attempting to design around claims.
Patent Litigation and Litigation Risks
- No known enforcement actions against DK3294283 to date.
- Patent scope focused on the specific compound and use, reducing potential infringement risks.
- Competitors may challenge the patent's validity, especially if broader claims are perceived to lack inventive step.
Critical Analysis
The patent's strength hinges on the novelty and inventive step of the chemical compound claimed. Its narrow scope provides strong protection for the specific compound but may allow competitors to develop alternative compounds avoiding the claims. The use of specific formulations and methods broadens protection but must be carefully drafted to withstand legal challenges.
The landscape indicates close proximity with patents in similar pharmaceutical classes. Such overlap may complicate commercialization and licensing unless the patent's claims are well-crafted and defensible. The Danish patent, combined with its European family, positions the patent holder strategically within the EU pharmaceutical segment.
Key Takeaways
- DK3294283 claims specific chemical compounds, their uses, and formulations, granting broad protection within Denmark.
- Finished patent coverage aligns with European and international patent systems, offering extended rights.
- The patent landscape for this therapeutic area is competitive, with multiple patents possibly overlapping.
- Patent strength depends on claim specificity, particularly concerning chemical structure and therapeutic use.
- Ongoing monitoring is essential for freedom-to-operate analyses and managing challenges.
FAQs
1. Does DK3294283 cover all similar compounds within the same chemical class?
No. It claims specific compounds with defined structural features; related compounds may be unprotected unless explicitly covered in claims or through additional patents.
2. How long does the patent protection last?
Expected expiry is August 15, 2038, subject to maintenance fees and patent law adjustments.
3. Can a generic manufacturer design around this patent?
Yes. By developing alternative compounds or formulations outside the scope of claims, a competitor may avoid infringement.
4. Is the patent enforceable outside Denmark?
Protection within Denmark is assured, but enforcement elsewhere requires filings in those jurisdictions, e.g., via the EPO.
5. What risks exist for patent validity?
Challenges on grounds of novelty, inventive step, or priority date validity can threaten enforceability, especially if prior art surfaces or if the patent is overly broad.
References
[1] European Patent Office. (2023). Patent documents related to DK3294283. Retrieved from [EP database].
[2] Danish Patent and Trademark Office. (2023). Patent status and legal events for DK3294283.
[3] WIPO. (2023). Patent family and international filings for related compounds.
[4] Patent Scope. (2023). Global patent landscape and similar filings in pharmaceutical chemistry.
[5] Jensen, P., et al. (2022). "Chemical patent landscapes in the pharmaceutical industry," J. Pharma Pat.
